Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Genome-wide imputation study identifies novel HLA locus for pulmonary fibrosis and potential role for auto-immunity in fibrotic idiopathic interstitial pneumonia.

Fingerlin TE, Zhang W, Yang IV, Ainsworth HC, Russell PH, Blumhagen RZ, Schwarz MI, Brown KK, Steele MP, Loyd JE, Cosgrove GP, Lynch DA, Groshong S, Collard HR, Wolters PJ, Bradford WZ, Kossen K, Seiwert SD, du Bois RM, Garcia CK, Devine MS, Gudmundsson G, Isaksson HJ, Kaminski N, Zhang Y, Gibson KF, Lancaster LH, Maher TM, Molyneaux PL, Wells AU, Moffatt MF, Selman M, Pardo A, Kim DS, Crapo JD, Make BJ, Regan EA, Walek DS, Daniel JJ, Kamatani Y, Zelenika D, Murphy E, Smith K, McKean D, Pedersen BS, Talbert J, Powers J, Markin CR, Beckman KB, Lathrop M, Freed B, Langefeld CD, Schwartz DA.

BMC Genet. 2016 Jun 7;17(1):74. doi: 10.1186/s12863-016-0377-2.

2.

Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study.

Noth I, Zhang Y, Ma SF, Flores C, Barber M, Huang Y, Broderick SM, Wade MS, Hysi P, Scuirba J, Richards TJ, Juan-Guardela BM, Vij R, Han MK, Martinez FJ, Kossen K, Seiwert SD, Christie JD, Nicolae D, Kaminski N, Garcia JGN.

Lancet Respir Med. 2013 Jun;1(4):309-317. doi: 10.1016/S2213-2600(13)70045-6. Epub 2013 Apr 17.

3.

Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis.

Peljto AL, Zhang Y, Fingerlin TE, Ma SF, Garcia JG, Richards TJ, Silveira LJ, Lindell KO, Steele MP, Loyd JE, Gibson KF, Seibold MA, Brown KK, Talbert JL, Markin C, Kossen K, Seiwert SD, Murphy E, Noth I, Schwarz MI, Kaminski N, Schwartz DA.

JAMA. 2013 Jun 5;309(21):2232-9. doi: 10.1001/jama.2013.5827.

4.

Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.

Jiang Y, Andrews SW, Condroski KR, Buckman B, Serebryany V, Wenglowsky S, Kennedy AL, Madduru MR, Wang B, Lyon M, Doherty GA, Woodard BT, Lemieux C, Geck Do M, Zhang H, Ballard J, Vigers G, Brandhuber BJ, Stengel P, Josey JA, Beigelman L, Blatt L, Seiwert SD.

J Med Chem. 2014 Mar 13;57(5):1753-69. doi: 10.1021/jm400164c. Epub 2013 May 28.

PMID:
23672640
5.

Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis.

Fingerlin TE, Murphy E, Zhang W, Peljto AL, Brown KK, Steele MP, Loyd JE, Cosgrove GP, Lynch D, Groshong S, Collard HR, Wolters PJ, Bradford WZ, Kossen K, Seiwert SD, du Bois RM, Garcia CK, Devine MS, Gudmundsson G, Isaksson HJ, Kaminski N, Zhang Y, Gibson KF, Lancaster LH, Cogan JD, Mason WR, Maher TM, Molyneaux PL, Wells AU, Moffatt MF, Selman M, Pardo A, Kim DS, Crapo JD, Make BJ, Regan EA, Walek DS, Daniel JJ, Kamatani Y, Zelenika D, Smith K, McKean D, Pedersen BS, Talbert J, Kidd RN, Markin CR, Beckman KB, Lathrop M, Schwarz MI, Schwartz DA.

Nat Genet. 2013 Jun;45(6):613-20. doi: 10.1038/ng.2609. Epub 2013 Apr 14. Erratum in: Nat Genet. 2013 Nov;45(11):1409.

6.

Virologic escape during danoprevir (ITMN-191/RG7227) monotherapy is hepatitis C virus subtype dependent and associated with R155K substitution.

Lim SR, Qin X, Susser S, Nicholas JB, Lange C, Herrmann E, Hong J, Arfsten A, Hooi L, Bradford W, Nájera I, Smith P, Zeuzem S, Kossen K, Sarrazin C, Seiwert SD.

Antimicrob Agents Chemother. 2012 Jan;56(1):271-9. doi: 10.1128/AAC.05636-11. Epub 2011 Nov 7.

7.

Recent advances in drug discovery of benzothiadiazine and related analogs as HCV NS5B polymerase inhibitors.

Das D, Hong J, Chen SH, Wang G, Beigelman L, Seiwert SD, Buckman BO.

Bioorg Med Chem. 2011 Aug 15;19(16):4690-703. doi: 10.1016/j.bmc.2011.06.079. Epub 2011 Jul 1. Review.

PMID:
21798747
8.

Antiviral activity of danoprevir (ITMN-191/RG7227) in combination with pegylated interferon α-2a and ribavirin in patients with hepatitis C.

Forestier N, Larrey D, Marcellin P, Guyader D, Patat A, Rouzier R, Smith PF, Qin X, Lim S, Bradford W, Porter S, Seiwert SD, Zeuzem S.

J Infect Dis. 2011 Aug 15;204(4):601-8. doi: 10.1093/infdis/jir315.

PMID:
21791662
9.

Antifibrotic activities of pirfenidone in animal models.

Schaefer CJ, Ruhrmund DW, Pan L, Seiwert SD, Kossen K.

Eur Respir Rev. 2011 Jun;20(120):85-97. doi: 10.1183/09059180.00001111. Review.

10.

Danoprevir monotherapy decreases inflammatory markers in patients with chronic hepatitis C virus infection.

Schaefer CJ, Kossen K, Lim SR, Lin JH, Pan L, Bradford W, Smith PF, Seiwert SD.

Antimicrob Agents Chemother. 2011 Jul;55(7):3125-32. doi: 10.1128/AAC.00131-11. Epub 2011 Apr 18.

11.

Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study.

Forestier N, Larrey D, Guyader D, Marcellin P, Rouzier R, Patat A, Smith P, Bradford W, Porter S, Blatt L, Seiwert SD, Zeuzem S.

J Hepatol. 2011 Jun;54(6):1130-6. doi: 10.1016/j.jhep.2010.11.001. Epub 2011 Feb 24.

PMID:
21145848
12.

Optimization of the multiple enzymatic activities of the hepatitis C virus NS3 protein.

Misialek S, Rajagopalan R, Stevens SK, Beigelman L, Seiwert SD, Kossen K.

Anal Biochem. 2009 Nov 1;394(1):138-40. doi: 10.1016/j.ab.2009.07.007. Epub 2009 Jul 8.

PMID:
19591800
13.

HCV NS5B polymerase inhibitors 1: Synthesis and in vitro activity of 2-(1,1-dioxo-2H-[1,2,4]benzothiadiazin-3-yl)-1-hydroxynaphthalene derivatives.

Wang G, He Y, Sun J, Das D, Hu M, Huang J, Ruhrmund D, Hooi L, Misialek S, Ravi Rajagopalan PT, Stoycheva A, Buckman BO, Kossen K, Seiwert SD, Beigelman L.

Bioorg Med Chem Lett. 2009 Aug 1;19(15):4476-9. doi: 10.1016/j.bmcl.2009.05.063. Epub 2009 May 23.

PMID:
19502055
14.

HCV NS5B polymerase inhibitors 2: Synthesis and in vitro activity of (1,1-dioxo-2H-[1,2,4]benzothiadiazin-3-yl) azolo[1,5-a]pyridine and azolo[1,5-a]pyrimidine derivatives.

Wang G, Lei H, Wang X, Das D, Hong J, Mackinnon CH, Coulter TS, Montalbetti CA, Mears R, Gai X, Bailey SE, Ruhrmund D, Hooi L, Misialek S, Rajagopalan PT, Cheng RK, Barker JJ, Felicetti B, Schönfeld DL, Stoycheva A, Buckman BO, Kossen K, Seiwert SD, Beigelman L.

Bioorg Med Chem Lett. 2009 Aug 1;19(15):4480-3. doi: 10.1016/j.bmcl.2009.05.022. Epub 2009 May 9.

PMID:
19500983
15.

HCV NS5B polymerase inhibitors 3: Synthesis and in vitro activity of 3-(1,1-dioxo-2H-[1,2,4]benzothiadiazin-3-yl)-4-hydroxy-2H-quinolizin-2-one derivatives.

Wang G, Zhang L, Wu X, Das D, Ruhrmund D, Hooi L, Misialek S, Ravi Rajagopalan PT, Buckman BO, Kossen K, Seiwert SD, Beigelman L.

Bioorg Med Chem Lett. 2009 Aug 1;19(15):4484-7. doi: 10.1016/j.bmcl.2009.05.021. Epub 2009 May 9.

PMID:
19497737
16.

Inhibition and binding kinetics of the hepatitis C virus NS3 protease inhibitor ITMN-191 reveals tight binding and slow dissociative behavior.

Rajagopalan R, Misialek S, Stevens SK, Myszka DG, Brandhuber BJ, Ballard JA, Andrews SW, Seiwert SD, Kossen K.

Biochemistry. 2009 Mar 24;48(11):2559-68. doi: 10.1021/bi900038p.

PMID:
19209850
17.

Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227).

Seiwert SD, Andrews SW, Jiang Y, Serebryany V, Tan H, Kossen K, Rajagopalan PT, Misialek S, Stevens SK, Stoycheva A, Hong J, Lim SR, Qin X, Rieger R, Condroski KR, Zhang H, Do MG, Lemieux C, Hingorani GP, Hartley DP, Josey JA, Pan L, Beigelman L, Blatt LM.

Antimicrob Agents Chemother. 2008 Dec;52(12):4432-41. doi: 10.1128/AAC.00699-08. Epub 2008 Sep 29.

18.
19.

High-throughput ribozyme-based assays for detection of viral nucleic acids.

Kossen K, Vaish NK, Jadhav VR, Pasko C, Wang H, Jenison R, McSwiggen JA, Polisky B, Seiwert SD.

Chem Biol. 2004 Jun;11(6):807-15.

20.

Monitoring protein modification with allosteric ribozymes.

Vaish NK, Kossen K, Andrews LE, Pasko C, Seiwert SD.

Methods. 2004 Apr;32(4):428-36.

PMID:
15003605
21.

Zeptomole detection of a viral nucleic acid using a target-activated ribozyme.

Vaish NK, Jadhav VR, Kossen K, Pasko C, Andrews LE, McSwiggen JA, Polisky B, Seiwert SD.

RNA. 2003 Sep;9(9):1058-72.

22.

Monitoring post-translational modification of proteins with allosteric ribozymes.

Vaish NK, Dong F, Andrews L, Schweppe RE, Ahn NG, Blatt L, Seiwert SD.

Nat Biotechnol. 2002 Aug;20(8):810-5. Epub 2002 Jul 15.

PMID:
12118241
23.

RNA aptamers as pathway-specific MAP kinase inhibitors.

Seiwert SD, Stines Nahreini T, Aigner S, Ahn NG, Uhlenbeck OC.

Chem Biol. 2000 Nov;7(11):833-43.

24.

RNA editing in kinetoplastid protozoa.

Stuart K, Allen TE, Heidmann S, Seiwert SD.

Microbiol Mol Biol Rev. 1997 Mar;61(1):105-20. Review.

25.
26.

RNA editing: a mechanism for gRNA-specified uridylate insertion into precursor mRNA.

Kable ML, Seiwert SD, Heidmann S, Stuart K.

Science. 1996 Aug 30;273(5279):1189-95. Erratum in: Science 1996 Oct 4;274(5284):21.

PMID:
8703045
27.

Complexes from Trypanosoma brucei that exhibit deletion editing and other editing-associated properties.

Corell RA, Read LK, Riley GR, Nellissery JK, Allen TE, Kable ML, Wachal MD, Seiwert SD, Myler PJ, Stuart KD.

Mol Cell Biol. 1996 Apr;16(4):1410-8.

28.
29.

The ins and outs of editing RNA in kinetoplastids.

Seiwert SD.

Parasitol Today. 1995 Oct;11(10):362-8.

PMID:
15275398
30.

RNA editing: transfer of genetic information from gRNA to precursor mRNA in vitro.

Seiwert SD, Stuart K.

Science. 1994 Oct 7;266(5182):114-7.

PMID:
7524149
31.

Mutations in the conserved loop of human U5 snRNA generate use of novel cryptic 5' splice sites in vivo.

Cortes JJ, Sontheimer EJ, Seiwert SD, Steitz JA.

EMBO J. 1993 Dec 15;12(13):5181-9.

32.

Supplemental Content

Loading ...
Support Center